The factors driving the overall market growth include increasing number of cancer patients, reduction in the cost of radiotherapy, and rising government and non-government investments in research and development of cancer treatment. Increasing number of cancer reported cases have been the primary factor for the demand for radiotherapy. According to World Health Organization (WHO) 2018 data on cancer, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. Moreover, Cancer Research UK suggests that the population suffering from cancer is expected to increase in the future. The report suggests that there may be 27.5 million new cancer cases worldwide each year by 2040. As a result of rising cancer cases, government and non-government organizations have been investing in cancer research. Organizations, like Cancer Research UK (CRUK), has been actively involved in this pursuit for finding effective therapies, spending more than GBP 400 million a year on cancer research. Economies worldwide have also developed strategies to reduce the cost of radiotherapy, especially in middle-income and low-income economies. These strategies have helped the economies to save up to 50% cost for radiotherapy. These factors have positively affected and helped the growth of the market.

Neurological diseases are frequent in older adults, affecting around 55% of people aged 55 and older. They are associated with a high risk for adverse health outcomes, including mortality, disability, institutionalization, and hospitalization. Neurological diseases, like dementia and Parkinson’s disease, and strokes and headaches, are frequently encountered n eurological diseases in el derly patien ts. Neuromodula tion is an in tracranial, el ectrical neuromodulation therapy that has FDA approval for the treatment for several of the neurological diseases, such as bladder control, headache, tremors, chronic pain, stroke, minimally conscious state, and spinal cord injury, which are most found in the elderly population. There are multiple ways through which funding organizations, research teams, and non-profit organizations are collaborating with consumers to raise the awareness regarding this neurological diseases, globally. The educational campaigns also play a demanding role in making patients and families aware of the neurological diseases, particularly in the middle and low-income nations, where the focus of the government and healthcare facilities are geared more toward major disorders, such as Parkinson’s disease and Alzheimer's disease.

Neurology devices are used for the diagnosis and treatment of various neurological disorders. The report of the neurology devices market involves the study of different types of devices, including neurostimulation devices, neurosurgery devices, interventional neurology devices, cerebrospinal fluid management devices, and others. In addition, it covers the end users of the market, including hospitals, neurological clinics, and ambulatory care centers. Moreover, this report provides a detailed analysis of the current market trends and future estimations from 2019 to 2026.

The report provides market dynamics and trends related to the global nephrology devices market. In addition, it presents the market estimations and forecast of the market. It includes revenue generated from the sales of devices such as dialysis instrument, lithotripter, dialysis catheters, and other products, which are provided by key players. For the purpose of analysis, the global nephrology devices market is segmented into device type and region. The study estimates revenue generated from the sales of nephrology devices. On the basis of device type, the market is divided into dialysis instrument, lithotripter, dialysis catheters, and others. This further provides an understanding of the use of nephrology devices. Moreover, the report covers revenue generated from the sales of nephrology devices offered across regions such as North America, Europe, Asia-Pacific, and LAMEA.

The growth of the market studied is currently being driven by various factors, including the increasing pet ownership and animal health expenditure, increased burden of animal zoonotic diseases, and the growing pet insurance and animal health investments made by the pharmaceutical companies.  The recent years have observed an increasing adoption of pet animals every year. Not only the pet ownership, but also the number of farm population has increased at a steady rate. There is also a high adoption of pigs across billions of farms all over the world.  Moreover, there is an increase in the immune mediated diseases in animals, which has driven the market for new immunodiagnostic tests. ELISA is a highly sensitive means of detecting relatively low levels of molecules within a biological fluid. For this reason, it is a very commonly used immunodiagnostic test and is applied to a wide variety of samples from different body fluids.

The report provides market dynamics and trends related to the global veterinary imaging market. In addition, it presents the estimations and forecast of the market. The study estimates the revenue generated from the sales of veterinary imaging; however, it excludes the veterinary imaging service revenue. The valuations comprise revenue generated from veterinary imaging product such as instruments and reagent. Conversely, the report excludes revenue generated from post-sale services of veterinary imaging. For the purpose of analysis, the global veterinary imaging market is segmented into product, animal type, application, and region. The study estimates the revenue generated from the sales of instruments and reagent. The applications covered in the study include orthopedics & traumatology, oncology, cardiology, neurology, and other. The report covers the revenue generated from the sales of products related to veterinary imaging systems offered in regions such as North America, Europe, Asia-Pacific, and LAMEA.

The market studied is currently being driven by factors, such as the rising incidence of thyroid disorders, the increasing consumption of tobacco and alcohol, the increasing geriatric population and the rising sedentary lifestyle among the population. Over the last few years, there have been significant advancements in the specificity and sensitivity of thyroid testing, which has impacted the treatment for thyroid disorders. Thyroid stimulating hormone (TSH) measurement subsequently gained a dominant role in thyroid function testing, which facilitates cost effective disease screening, which is augmenting the demand across the developing and developed countries. While there are several problems associated with interpretation of thyroid blood tests but with the appropriate follow-up tests, and consultation, most of these cases can be resolved easily, which is expected to progressively improve the thyroid testing methods.

原料药不是简单周期板块，特色及专利原料药具有成长属性，行业壁垒相对较高：原料药分为大宗原料药、特色原料 药及专利原料药，其中大宗原料药需求相对平稳，而特色原料药和专利药原料药具备成长属性。2020年全球原料药市场 规模将预计达到1864亿美元，同比增长6.1%，特色原料药增速预计在6%-10%。从壁垒来看，大宗原料药门槛低，竞争 激烈，而特色原料药和专利原料药门槛较高；特色原料药核心壁垒体现在技术、重资产和客户粘性方面，在技术层面，生 产工艺和研发水平需要不断提高；在客户粘性方面，特色原料药和专利原料药与客户绑定紧密；重资产方面，特色原料药 专业化生产线需要较大资金投入，近几年环保成本攀升，进一步提高行业壁垒。